Seroatlas · Human Serome Atlas

ASPDH

Aspartate dehydrogenase domain-containing protein

Also known as: ASPDH_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: A6ND91
Gene: ASPDH
Ensembl: ENSG00000204653
Chromosome: 19
Canonical length: 283 aa
Protein class: Predicted intracellular proteins
Subcellular location: Nucleoplasm,Cytosol

OverviewNCBI Gene

Predicted to enable NADP binding activity and aspartate dehydrogenase activity. Predicted to be involved in NAD biosynthetic process. [provided by Alliance of Genome Resources, Apr 2025]

Canonical amino-acid sequenceUniProt

283 residues, UniProt reviewed canonical sequence.

>A6ND91|ASPDH
     1  MADRGPWRVG VVGYGRLGQS LVSRLLAQGP ELGLELVFVW NRDPGRMAGS VPPSLQLQNL
    61  AALGERRPDL VVEVAHPKII HESGAQILRH ANLLVGSPSA LSDQTTERQL LEASQHWDHA
   121  VFVARGALWG AEDIRRLDAA GGLRSLRVTM ATHPDGFRLE GPLAAAHSPG PCTVLYEGPV
   181  RGLCPFAPRN SNTMAAAALA APSLGFDGVI GVLVADTSLT DMHVVDVELS GPRGPTGRSF
   241  AVHTRRENPA EPGAVTGSAT VTAFWQSLLA CCQLPSRPGI HLC

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against ASPDH can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Unknown
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.26
Highest tissue expression: 129 nTPM

Expression across tissuesHPA

Tissue

liver: 129 nTPM
cerebral cortex: 40 nTPM
basal ganglia: 38 nTPM
kidney: 38 nTPM
hippocampal formation: 33 nTPM
amygdala: 31 nTPM

Single-cell type

hepatocytes: 175 nCPM
epididymal efferent duct absorptive cells: 30 nCPM
retinal bipolar cells: 20 nCPM
corticotrophs: 18 nCPM
epicardial cells: 14 nCPM
proximal tubule cells: 9.8 nCPM

Immune cell

basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM
MAIT T-cell: 0 nTPM

Brain region

cerebral cortex: 50 nTPM
cerebellum: 39 nTPM
thalamus: 38 nTPM
white matter: 34 nTPM
basal ganglia: 33 nTPM
hippocampal formation: 31 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.41
gnomAD pLI: 0
gnomAD missense Z: 0.45
DepMap mean gene effect: 0.04
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

NAD+ biosynthetic process

Molecular functions

NADP binding
aspartate dehydrogenase [NAD(P)+] activity

Protein domainsUniProt · Pfam · InterPro

NAD(P)-binding domain superfamily
Aspartate dehydrogenase
Aspartate/homoserine dehydrogenase, NAD-binding
L-aspartate dehydrogenase
Aspartate dehydrogenase, C-terminal
Homoserine dehydrogenase, NAD binding domain

KeywordsUniProt

Phosphoprotein

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads ASPDH as an antibody target. Whether an autoantibody or antibody against ASPDH could matter depends on whether native ASPDH is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

ASPDH is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label ASPDH as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...